Dear Sir, Please our Financial Results for the Quarter and Half year ended 30-9-2025 as required under Regulation 30 and 33 of SEBI (LODR), Regulation 2015. Kindly acknowledge the same.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts less than Nifty Microcap 250 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Colinz Laboratories reported Q2 FY26 revenue from operations of Rs. 138.80 lakhs, down from Rs. 186.31 lakhs in Q2 FY25, a decline of about 25%. Total income for the quarter stood at Rs. 154.73 lakhs versus Rs. 194.08 lakhs a year ago. Profit after tax for Q2 was Rs. 14.05 lakhs (EPS Rs. 0.56) compared to Rs. 15.57 lakhs (EPS Rs. 0.62) in the same quarter last year. For the half year ended September 2025, revenue from operations fell to Rs. 295.41 lakhs from Rs. 360.97 lakhs, while PAT was Rs. 25.97 lakhs versus Rs. 29.29 lakhs in H1 FY25. The statutory auditor Vora & Associates issued an unqualified review report with no qualifications or emphasis of matter.
The sharp year-on-year decline in both revenue and profit may weigh on the stock in the short term, though the company remains debt-light with healthy cash balances and continued positive operating cash flow of Rs. 166.19 lakhs.